Residual symptoms in depression: Can treatment be symptom-specific?

Journal of Clinical Psychiatry

Volumn 64, Issue 5, 2003, Pages 516-523

  Menza, Matthew ^a   Marin, Humberto ^b   Opper, Rachel Sokol ^b  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CLONAZEPAM; GABAPENTIN; METHYLPHENIDATE; MODAFINIL; NEUROLEPTIC AGENT; OLANZAPINE; PEMOLINE; PSYCHOSTIMULANT AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; THYROID HORMONE; TRAZODONE; VENLAFAXINE; ZALEPLON; ZOLPIDEM; ZOLPIDEM TARTRATE;

ANORGASMIA; ANXIETY DISORDER; DEPRESSION; DISABILITY; DRUG EFFICACY; ERECTILE DYSFUNCTION; FATIGUE; HUMAN; PALLIATIVE THERAPY; PRIORITY JOURNAL; PSYCHIATRIST; RELAPSE; REVIEW; SEXUAL DYSFUNCTION; SLEEP DISORDER; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 0038475697     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v64n0504     Document Type: Review

References (86)

1. Fava GA, Grandi S, Zielezny M, et al. Cognitive-behavioral treatment of residual symptoms in primary major depressive disorder. Am J Psychiatry 1994;151:1295-1299
2. Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 1999;60:221-225
3. Fawcett J. Antidepressants: partial response in chronic depression. Br J Psychiatry 1994;165:37-41
4. Cornwall P, Scott J. Partial remission in depressive disorders. Acta Psychiatr Scand 1997;95:265-271
5. Judd LL, Akiskal HS, Maser JD, et al. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry 1998;55:694-700
6. Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 1998;50:97-108
7. Thase ME, Simons AD, McGeary J, et al. Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatments. Am J Psychiatry 1992;149:1046-1052
8. Mintz J, Mintz LI, Arruda MJ, et al. Treatment of depression and the functional capacity to work. Arch Gen Psychiatry 1992;49:761-768
9. Paykel ES. Remission and residual symptomatology in major depression. Psychopathology 1998;31:5-14
10. Judd LL, Akiskal HS, Zeller PJ, et al. Psychosocial disability during the long-term course of unipolar major depressive disorder. Arch Gen Psychiatry 2000;57:375-380
11. Fava M. Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiatry 2001;62(suppl 18):4-11
12. Thase ME, Howland RH, Friedman ES. Treating antidepressant nonresponders with augmentation strategies: an overview. J Clin Psychiatry 1998;59(suppl 5):5-12
13. Fava GA, Kellner R, Munari F, et al. The Hamilton Depression Rating Scale in normals and depressives: a cross cultural validation. Acta Psychiatr Scand 1982;66:26-32
14. Montgomery S, Dufour H, Brion S, et al. The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry Suppl 1988;3:69-76
15. Shea MT, Elkin I, Imber SD, et al. Course of depressive symptoms over follow-up: findings from the NIMH Treatment of Depression Collaborative Research Program. Arch Gen Psychiatry 1992;49:782-787
16. Keller MB, Lavori PW, Mueller TI, et al. Time to recovery, chronicity, and levels of psychopathology in major depression: a 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 1992;49:809-816
17. Reynolds CF, Frank E, Perel JM, et al. Combined pharmacotherapy and psychotherapy in the acute and continuation treatment of elderly patients with recurrent major depression: a preliminary report. Am J Psychiatry 1992;149:1687-1692
18. Taylor S, McLean P. Outcome profiles in the treatment of unipolar depression. Behav Res Ther 1993;31:325-330
19. Salomon DA, Keller MB, Leon AC, et al. Recovery major depression: a 10-year prospective follow-up across multiple episodes. Arch Gen Psychiatry 1997;54:1001-1006
20. Mojtabai R. Residual symptoms and impairment in major depression in the community. Am J Psychiatry 2001;158:1645-1651
21. Frank E, Kupfer D, Perel J, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990;47: 1093-1099
22. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definition of terms in major depressive disorder. Arch Gen Psychiatry 1991;48:851-855
23. Prien RF, Carpenter LL, Kupfer DJ. The definition and operational criteria for treatment outcome of major depressive disorder. Arch Gen Psychiatry 1991;48:796-800
24. Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry 2001;62(suppl 16):5-9
25. Judd LL, Akiskal HS, Paulus MP. The role and clinical significance of subsyndromal depressive symptoms (SSD) in unipolar major depressive disorder. J Affect Disord 1997;45:5-18
26. Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995;25:1171-1180
27. Faravelli C, Ambonetti A, Planti S, et al. Depressive relapses and incomplete recovery from index episode. Am J Psychiatry 1986;49:888-891
28. Mindham RH, Howland C, Sheperd M. An evaluation of continuation therapy with tricyclic antidepressants in depressive illness. Psychol Med 1973;3:5-17
29. Prien RF, Kupfer DJ. Continuous drug therapy for major depressive episodes: how long should it be maintained? Am J Psychiatry 1986; 143: 18-23
30. Paykel ES, Scott J, Teasdale JD, et al. Prevention of relapse in residual depression by cognitive therapy. Arch Gen Psychiatry 1999;56:829-835
31. Moos RH, Cronkite RC. Symptom-based predictors of a 10-year chronic course of treated depression. J Nerv Ment Dis 1999;187:360-368
32. Tylee A, Gastpar M, Lepine JP, et al, for the DEPRES Steering Committee. DEPRES II (Depression Research in European Society II): a patient survey of the symptoms, disability and current management of depression in the community. Int Clin Psychopharmacol 1999;14:139-151
33. Baker M, Dorzab J, Winokur G, et al. Depressive disease: classification and clinical characteristics. Compr Psychiatry 1971;12:354-365
34. Hallerstein DJ, Yanowitch P, Rosenthal J, et al. A randomized doubleblind study of fluoxetine versus placebo in the treatment of dysthymia. Am J Psychiatry 1993;150:1169-1175
35. Chiarello RJ, Cole JO. The use of psychostimulants in general psychiatry. Arch Gen Psychiatry 1987;44:286-295
36. Robin AA, Wiseberg S. A controlled trial of methylphenidate (Ritalin) in the treatment of depressive states. J Neurol Neurosurg Psychiatry 1958; 21:55-57
37. Elizur A, Wintner I, Davidson S. The clinical and psychological effects of pemoline in depressed patients: a controlled study. Int Pharmacopsychiatry 1979;14:127-134
38. Masand PS, Tesar GE. Use of stimulants in the medically ill. Psychiatr Clin North Am 1996;19:515-547
39. Menza MA, Kaufman K, Castellanos A. Modafinil augmentation of antidepressant treatment in depression. J Clin Psychiatry 2000;61:378-381
40. DeBatista C, Solvason HB, Flores BH, et al. Modafinil as an adjunctive agent in the treatment of fatigue and hypersomnia associated with depression. Presented at the 39th annual meeting of the American College of Neuropsychopharmacology; Dec 10-14, 2000; San Juan, Puerto Rico
41. Judge R, Plewes JM, Kumar V, et al. Changes in energy during treatment of depression: an analysis of fluoxetine in double-blind, placebocontrolled trials. J Clin Psychopharmacol 2000;20:666-672
42. Green TR. Bupropion for SSRI-induced fatigue [letter]. J Clin Psychiatry 1997;59:174
43. Goodnick PJ. Treatment of chronic fatigue with venlafaxine [letter]. Am J Psychiatry 1996;153:294
44. Joffe RT. Refractory depression: treatment strategies, with particular reference to the thyroid axis. J Psychiatry Neurosci 1997;22:327-331
45. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999;281:537-544
46. Kennedy SH, Dickens SE, Eisfeld BS, et al. Sexual dysfunction before antidepressant therapy in major depression. J Affect Disord 1999;56: 201-208
47. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999;19:67-85
48. Montejo AL, Llorca G, Izquierdo JA, et al, for the Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. J Clin Psychiatry 2001;62(suppl 3):10-21
49. Michelson D, Schmidt M, Lee J, et al. Changes in sexual function during acute and six-month fluoxetine therapy: a prospective assessment. J Sex Marital Ther 2001;27:289-302
50. Seidman SN, Roose SP, Menza M, et al. Treatment of erectile dysfunction in men with depressive symptoms: results of a placebo-controlled trial with sildenafil citrate. Am J Psychiatry 2001;158:1623-1630
51. Nurnberg H, Lauriello J, Hensley P, et al. Sildenafil for sexual dysfunction in women taking antidepressants [letter]. Am J Psychiatry 1999;156:1664
52. Nurnberg HG, Gelenberg A, Hargreave TB, et al. Efficacy of sildenafil citrate for the treatment of erectile dysfunction in men taking serotonin reuptake inhibitors. Am J Psychiatry 2001;158:1926-1928
53. Modell JG, Katholi CR, Modell JD, et al. Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. Clin Pharmacol Ther 1997;61:476-487
54. Segraves RT, Croft H, Kavoussi R, et al. Bupropion sustained release (SR) for the treatment of hypoactive sexual desire disorder (HSDD) in nondepressed women. J Sex Marital Ther 2001;27:303-316
55. Modell JG, May RS, Katholi CR. Effect of bupropion SR on orgasmic dysfunction in nondepressed subjects: a pilot study. J Sex Marital Ther 2000;26:231-240
56. Rowland DL, Myers L, Culver A, et al. Bupropion and sexual function: a placebo-controlled prospective study on diabetic men with erectile dysfunction. J Clin Psychopharmacol 1997;17:350-357
57. Boyarsky BK, Haque W, Rouleau MR, et al. Sexual functioning in depressed outpatients taking mirtazapine. Depress Anxiety 1999;9:175-179
58. Labbate LA, Grimes JB, Hines A, et al. Bupropion treatment of serotonin reuptake antidepressant-associated sexual dysfunction. Ann Clin Psychiatry 1997;9:241-245
59. Hirschfeld RMA. Care of the sexually active depressed patient. J Clin Psychiatry 1999;60(suppl 17):32-35
60. Fawcett J, Kravitz HM. Anxiety syndromes and their relationship to depressive illness. J Clin Psychiatry 1983;44(8 pt 2):8-11
61. Kessler RC, Nelson CB, McGonagle KA, et al. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US national comorbidity survey. Br J Psychiatry 1996;168(suppl 30):17-30
62. Parker G, Wilhelm K, Asghari A. Early onset depression: the relevance of anxiety. Soc Psychiatry Psychiatr Epidemiol 1997;32:30-37
63. Fava M, Rankin MA, Wright EC, et al. Anxiety disorders in major depression. Compr Psychiatry 2000;41:97-102
64. Ballenger JC. Comorbidity of panic and depression: implications for clinical management. Int Clin Psychopharmacol 1998;13(suppl 4): S13-S17
65. Grunhaus L, Rabin D, Greden JF. Simultaneous panic and depressive disorders: response to antidepressant treatment. J Clin Psychiatry 1986;47:4-7
66. Gaynes BN, Magruder KM, Burns BJ, et al. Does a coexisting anxiety disorder predict persistence of depressive illness in primary care patients with major depression? Gen Hosp Psychiatry 1999;21:158-167
67. Lydiard RB, Brawman-Mintzer O. Anxious depression. J Clin Psychiatry 1998;59(suppl 18):10-17
68. Lydiard RB. Coexisting depression and anxiety: special diagnostic and treatment issues. J Clin Psychiatry 1991;52(suppl 6):48-54
69. Tylee A, Gaspar M, Lepine JP, et al. Identification of depressed patient types in the community and their treatment needs: finding from the DEPRES II (Depression Research in European Society II) survey. Int Clin Psychopharmacol 1999;14:153-165
70. Rapaport MH. Prevalence, recognition, and treatment of comorbid depression and anxiety. J Clin Psychiatry 2001;62(suppl 24):6-10
71. Laws D, Ashford JJ, Anstee JA. A multicentre double-blind comparative trial of fluvoxamine versus lorazepam in mixed anxiety and depression treated in general practice. Acta Psychiatr Scand 1990;81:185-189
72. Morishita S, Aoki S. Clonazepam in the treatment of prolonged depression. J Affect Disord 1999;53:275-278
73. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999;60: 256-259
74. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158:131-134
75. Wilner KD, Anziano RJ, Johnson AC, et al. The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery. J Clin Psychopharmacol 2002;22:206-210
76. Tollefson GD, Sanger TM, Beasley CM, et al. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biol Psychiatry 1998;43:803-810
77. Appelberg BG, Syvalahti EK, Koskinen TE, et al. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry 2001;62:448-452
78. Breslau N, Roth T, Rosenthal L, et al. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry 1996;39:411-418
79. Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders: an opportunity for prevention? JAMA 1989; 262:1479-1484
80. Hatoum HT, Kong SX, Kania CM, et al. Insomnia, health-related quality of life and health care resource consumption: a study of managed care organization enrollees. Pharmacoeconomics 1998;14:629-637
81. Weyerer S, Dilling H. Prevalence and treatment of insomnia in the community: results from the Upper Bavarian Field Study. Sleep 1991; 14:392-398
82. Fawcett J, Scheftner WA, Fogg L, et al. Time-related predictors of suicide in major affective disorder. Am J Psychiatry 1990;147:1189-1194
83. Wingard DL, Berkman LF. Mortality risk associated with sleeping patterns among adults. Sleep 1983;6:102-107
84. Thase ME. Depression, sleep, and antidepressants. J Clin Psychiatry 1998;59(suppl 4):55-65
85. Asnis GM, Chakraburtty A, DuBoff EA, et al. Zolpidem for persistent insomnia in SSRI-treated depressed patients. J Clin Psychiatry 1999; 60:668-676
86. Rush JA, Batey SR, Donahue RMJ, et al. Does pretreatment anxiety predict response to either bupropion SR or sertraline? J Affect Disord 2001;64:81-87